Results: 11
Authors' Reply to Michael Auerbach's Comment on: "Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System"
- Published in:
- 2021
- By:
- Publication type:
- Letter
An Update of the North American Chapter of the International Society of Pharmacovigilance (NASoP).
- Published in:
- 2021
- By:
- Publication type:
- Editorial
Comment on: Frequency and Associated Costs of Anaphylaxis- and Hypersensitivity-Related Adverse Events for Intravenous Iron Products in the USA: An Analysis Using the US Food and Drug Administration Adverse Event Reporting System.
- Published in:
- 2021
- By:
- Publication type:
- Letter
Clinical Utility of Pharmacogenomic Data Collected by a Health-System Biobank to Predict and Prevent Adverse Drug Events.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Assessing the Impact on Health of Pharmacovigilance Activities: Example of Four Safety Signals.
- Published in:
- Drug Safety, 2021, v. 44, n. 5, p. 589, doi. 10.1007/s40264-021-01047-1
- By:
- Publication type:
- Article
Adverse Drug Reactions from Real-World Data in Inflammatory Bowel Disease Patients in the IBDREAM Registry.
- Published in:
- Drug Safety, 2021, v. 44, n. 5, p. 581, doi. 10.1007/s40264-021-01045-3
- By:
- Publication type:
- Article
Identification and Validation of Major Cardiovascular Events in the United Kingdom Data Sources Included in a Multi-database Post-authorization Safety Study of Prucalopride.
- Published in:
- Drug Safety, 2021, v. 44, n. 5, p. 541, doi. 10.1007/s40264-021-01044-4
- By:
- Publication type:
- Article
Anticholinergic Activity of Psychotropic Drugs and Cognitive Impairment Among Participants Aged 45 and Over: The CONSTANCES Study.
- Published in:
- Drug Safety, 2021, v. 44, n. 5, p. 565, doi. 10.1007/s40264-021-01043-5
- By:
- Publication type:
- Article
Public Perspectives of Using Social Media Data to Improve Adverse Drug Reaction Reporting: A Mixed-Methods Study.
- Published in:
- Drug Safety, 2021, v. 44, n. 5, p. 553, doi. 10.1007/s40264-021-01042-6
- By:
- Publication type:
- Article
Population-Based Observational Study of Adverse Drug Event-Related Mortality in the Super-Aged Society of Japan.
- Published in:
- Drug Safety, 2021, v. 44, n. 5, p. 531, doi. 10.1007/s40264-020-01037-9
- By:
- Publication type:
- Article
Upadacitinib in Rheumatoid Arthritis: A Benefit–Risk Assessment Across a Phase III Program.
- Published in:
- Drug Safety, 2021, v. 44, n. 5, p. 515, doi. 10.1007/s40264-020-01036-w
- By:
- Publication type:
- Article